Dongwha Pharm.Co.,Ltd (KRX:000020)

South Korea · Delayed Price · Currency is KRW

4,760.00

+80.00 (1.71%)

Aug 3, 2026, 3:30 PM KST

-26.20% (1Y)

Market Cap	131.94B -29.7%
Revenue (ttm)	501.33B +6.3%
Net Income	18.67B +615.5%
EPS	716.34 +705.1%
Shares Out	27.72M
PE Ratio	6.64
Forward PE	n/a
Dividend	180.00 (3.85%)
Ex-Dividend Date	Mar 24, 2026

Volume	145,679
Open	4,680.00
Previous Close	4,680.00
Day's Range	4,640.00 - 4,840.00
52-Week Range	4,450.00 - 7,560.00
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Dongwha Pharm.Co.,Ltd

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health su... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1897

Employees 826

Stock Exchange Korea Stock Exchange

Ticker Symbol 000020

Full Company Profile

Financial Performance

In 2025, Dongwha Pharm.Co.,Ltd's revenue was 496.39 billion, an increase of 6.78% compared to the previous year's 464.87 billion. Earnings were 8.69 billion, an increase of 56.13%.

Financial Statements